SCHEMBL6733037

SCHEMBL6733037

COC(=O)c1cccc2nc(N3CCCC[C@H]3C(=O)O)oc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.47
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 4/20 0.40
HPGD P15428 2/20 0.40
HTR3A P46098 2/20 0.39
RIPK1 Q13546 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
PKM P14618 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
ESR1 P03372 1/20 0.36
MAPT P10636 1/20 0.36
MAPK10 P53779 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7808542 1.00 ELANE (0.47) ELANEALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL6740586 0.82 ELANE (0.38) ELANEALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL6740591 0.81 ALDH1A1 (0.41) ELANEALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL6734500 0.81 ALDH1A1 (0.41) ELANEALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL7685083 0.76 ELANE (0.56) ELANEALDH1A1KMT2AHSD17B10HPGD
SCHEMBL6733860 0.76 ELANE (0.56) ELANEALDH1A1KMT2AHSD17B10HPGD
Hydrochloric Acid SCHEMBL7654203 0.75 ELANE (0.55) ELANEALDH1A1KMT2AHSD17B10HPGD
SCHEMBL27479845 0.73 LMNA (0.51) ELANEALDH1A1KMT2AHTR3ATSHR
SCHEMBL2316032 0.73 ELANE (0.60) ELANEALDH1A1KMT2AHSD17B10HPGD
SCHEMBL2313692 0.73 ELANE (0.60) ELANEALDH1A1KMT2AHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058905-A1 Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes PFIZER INC. 2004-03-25 US disclosed
US-6686357-B1 BENZIMIDAZOLO-PIPERIDINE COMPOUND PFIZER, INC. 2004-02-03 US disclosed
US-6509464-B1 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation PFIZER INC 2003-01-21 US disclosed
US-6495549-B1 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE PFIZER INC 2002-12-17 US disclosed
EP-1098894-B1 FKBP INHIBITORS PFIZER LTD (GB) 2002-10-02 EP disclosed
US-6166011-A FKBP inhibitors PFIZER INC (US) 2000-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058905-A1 Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes FKBP1A, FKBP4, FKBP1B ELANE 4209/4885ALDH1A1 983/4885KDM4E 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.